RAPID postmarketing study - medicinal cannabis
RAPID is a quality improvement program looking at the prospective use of medications and non-pharmacological interventions commonly used in palliative and supportive care. RAPID enable prospective monitoring of a medication that is already available and where the evidence underpinning its use is limited.
To capture the benefits or effects, as well as adverse effects of medicinal cannabis.
Potential Impact Since increased availability of medicinal cannabis, the opportunity o accrue evidence of either benefit or toxicity from prescribed cannabis must be undertaken in a post-marketing context. The data form this study will importantly inform practices that are currently being undertaken without strong evidence.